Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | (-)-epigallocatechin 3-gallate | multiple interactions | ISO | ZNF287 (Homo sapiens) | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF287 mRNA | CTD | PMID:22079256 | 1,2-dimethylhydrazine | decreases expression | EXP | | 6480464 | 1 and 2-Dimethylhydrazine results in decreased expression of ZFP287 mRNA | CTD | PMID:22206623 | 17beta-estradiol | multiple interactions | ISO | Zfp287 (Rattus norvegicus) | 6480464 | [bisphenol A co-treated with Estradiol] results in increased expression of ZFP287 mRNA | CTD | PMID:26496021 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of ZFP287 mRNA | CTD | PMID:24058054 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | Zfp287 (Rattus norvegicus) | 6480464 | Tetrachlorodibenzodioxin results in increased expression of ZFP287 mRNA | CTD | PMID:33387578 | 2-hydroxypropanoic acid | decreases expression | ISO | ZNF287 (Homo sapiens) | 6480464 | Lactic Acid results in decreased expression of ZNF287 mRNA | CTD | PMID:30851411 | 3,4-methylenedioxymethamphetamine | increases expression | EXP | | 6480464 | N-Methyl-3 and 4-methylenedioxyamphetamine results in increased expression of ZFP287 mRNA | CTD | PMID:20188158 | 3-isobutyl-1-methyl-7H-xanthine | multiple interactions | ISO | ZNF287 (Homo sapiens) | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ZNF287 mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of ZNF287 mRNA | CTD | PMID:28628672 | 4,4'-sulfonyldiphenol | multiple interactions | ISO | ZNF287 (Homo sapiens) | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of ZNF287 mRNA | CTD | PMID:28628672 | acrylamide | decreases expression | ISO | Zfp287 (Rattus norvegicus) | 6480464 | Acrylamide results in decreased expression of ZFP287 mRNA | CTD | PMID:28959563 | amphetamine | decreases expression | ISO | Zfp287 (Rattus norvegicus) | 6480464 | Amphetamine results in decreased expression of ZFP287 mRNA | CTD | PMID:30779732 | benzo[a]pyrene | increases methylation | ISO | ZNF287 (Homo sapiens) | 6480464 | Benzo(a)pyrene results in increased methylation of ZNF287 promoter | CTD | PMID:27901495 | benzo[a]pyrene | decreases methylation | ISO | ZNF287 (Homo sapiens) | 6480464 | Benzo(a)pyrene results in decreased methylation of ZNF287 5' UTR | CTD | PMID:27901495 | bisphenol A | multiple interactions | ISO | Zfp287 (Rattus norvegicus) | 6480464 | [bisphenol A co-treated with Estradiol] results in increased expression of ZFP287 mRNA | CTD | PMID:26496021 | bisphenol A | multiple interactions | ISO | ZNF287 (Homo sapiens) | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ZNF287 mRNA | CTD | PMID:28628672 | bisphenol A | increases expression | ISO | Zfp287 (Rattus norvegicus) | 6480464 | bisphenol A results in increased expression of ZFP287 mRNA | CTD | PMID:30816183 and PMID:32528016 | bisphenol A | decreases expression | ISO | Zfp287 (Rattus norvegicus) | 6480464 | bisphenol A results in decreased expression of ZNF287 mRNA | CTD | PMID:25181051 | cadmium dichloride | affects expression | EXP | | 6480464 | Cadmium Chloride affects the expression of ZFP287 mRNA | CTD | PMID:18974090 | carbon nanotube | decreases expression | EXP | | 6480464 | Nanotubes more ... | CTD | PMID:25554681 | curcumin | increases expression | ISO | ZNF287 (Homo sapiens) | 6480464 | Curcumin results in increased expression of ZNF287 mRNA | CTD | PMID:18421014 | dexamethasone | multiple interactions | ISO | ZNF287 (Homo sapiens) | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ZNF287 mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of ZNF287 mRNA | CTD | PMID:28628672 | dorsomorphin | multiple interactions | ISO | ZNF287 (Homo sapiens) | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | entinostat | decreases expression | ISO | ZNF287 (Homo sapiens) | 6480464 | entinostat results in decreased expression of ZNF287 mRNA | CTD | PMID:26272509 | entinostat | multiple interactions | ISO | ZNF287 (Homo sapiens) | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF287 mRNA | CTD | PMID:27188386 | gentamycin | decreases expression | ISO | Zfp287 (Rattus norvegicus) | 6480464 | Gentamicins results in decreased expression of ZFP287 mRNA | CTD | PMID:33387578 | indometacin | multiple interactions | ISO | ZNF287 (Homo sapiens) | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ZNF287 mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of ZNF287 mRNA | CTD | PMID:28628672 | iron dichloride | decreases expression | ISO | ZNF287 (Homo sapiens) | 6480464 | ferrous chloride results in decreased expression of ZNF287 mRNA | CTD | PMID:35984750 | maneb | multiple interactions | EXP | | 6480464 | [Maneb co-treated with Paraquat] results in decreased expression of ZFP287 mRNA | CTD | PMID:36117858 | mercury dibromide | decreases expression | ISO | ZNF287 (Homo sapiens) | 6480464 | mercuric bromide results in decreased expression of ZNF287 mRNA | CTD | PMID:26272509 | mercury dibromide | multiple interactions | ISO | ZNF287 (Homo sapiens) | 6480464 | [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF287 mRNA | CTD | PMID:27188386 | methamphetamine | multiple interactions | ISO | Zfp287 (Rattus norvegicus) | 6480464 | [Methamphetamine co-treated with SCH 23390] results in decreased expression of ZFP287 mRNA | CTD | PMID:19564919 | methamphetamine | increases expression | ISO | Zfp287 (Rattus norvegicus) | 6480464 | Methamphetamine results in increased expression of ZFP287 mRNA | CTD | PMID:19564919 | methylmercury chloride | decreases expression | ISO | ZNF287 (Homo sapiens) | 6480464 | methylmercuric chloride results in decreased expression of ZNF287 mRNA | CTD | PMID:28001369 | nickel atom | decreases expression | ISO | ZNF287 (Homo sapiens) | 6480464 | Nickel results in decreased expression of ZNF287 mRNA | CTD | PMID:25583101 | nickel sulfate | decreases expression | ISO | ZNF287 (Homo sapiens) | 6480464 | nickel sulfate results in decreased expression of ZNF287 mRNA | CTD | PMID:22714537 | p-chloromercuribenzoic acid | decreases expression | ISO | ZNF287 (Homo sapiens) | 6480464 | p-Chloromercuribenzoic Acid results in decreased expression of ZNF287 mRNA | CTD | PMID:26272509 | p-chloromercuribenzoic acid | multiple interactions | ISO | ZNF287 (Homo sapiens) | 6480464 | [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF287 mRNA | CTD | PMID:27188386 | panobinostat | multiple interactions | ISO | ZNF287 (Homo sapiens) | 6480464 | [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF287 mRNA | CTD | PMID:27188386 | paracetamol | increases expression | ISO | Zfp287 (Rattus norvegicus) | 6480464 | Acetaminophen results in increased expression of ZFP287 mRNA | CTD | PMID:33387578 | paraquat | multiple interactions | EXP | | 6480464 | [Maneb co-treated with Paraquat] results in decreased expression of ZFP287 mRNA | CTD | PMID:36117858 | phenylmercury acetate | decreases expression | ISO | ZNF287 (Homo sapiens) | 6480464 | Phenylmercuric Acetate results in decreased expression of ZNF287 mRNA | CTD | PMID:26272509 | phenylmercury acetate | multiple interactions | ISO | ZNF287 (Homo sapiens) | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF287 mRNA | CTD | PMID:27188386 | pirinixic acid | multiple interactions | ISO | ZNF287 (Homo sapiens) | 6480464 | [pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of ZNF287 mRNA | CTD | PMID:19710929 | potassium chloride | multiple interactions | ISO | ZNF287 (Homo sapiens) | 6480464 | [Dronabinol results in decreased susceptibility to Potassium Chloride] which results in decreased expression of ZNF287 mRNA | CTD | PMID:29691375 | potassium chromate | decreases expression | ISO | ZNF287 (Homo sapiens) | 6480464 | potassium chromate(VI) results in decreased expression of ZNF287 mRNA | CTD | PMID:22079256 | potassium chromate | multiple interactions | ISO | ZNF287 (Homo sapiens) | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF287 mRNA | CTD | PMID:22079256 | potassium dichromate | increases expression | EXP | | 6480464 | Potassium Dichromate results in increased expression of ZFP287 mRNA | CTD | PMID:23608068 | rac-lactic acid | decreases expression | ISO | ZNF287 (Homo sapiens) | 6480464 | Lactic Acid results in decreased expression of ZNF287 mRNA | CTD | PMID:30851411 | resveratrol | multiple interactions | ISO | ZNF287 (Homo sapiens) | 6480464 | [Plant Extracts co-treated with Resveratrol] results in increased expression of ZNF287 mRNA | CTD | PMID:23557933 | SB 431542 | multiple interactions | ISO | ZNF287 (Homo sapiens) | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | SCH 23390 | multiple interactions | ISO | Zfp287 (Rattus norvegicus) | 6480464 | [Methamphetamine co-treated with SCH 23390] results in decreased expression of ZFP287 mRNA | CTD | PMID:19564919 | SCH 23390 | decreases expression | ISO | Zfp287 (Rattus norvegicus) | 6480464 | SCH 23390 results in decreased expression of ZFP287 mRNA | CTD | PMID:19564919 | sodium arsenite | decreases expression | ISO | ZNF287 (Homo sapiens) | 6480464 | sodium arsenite results in decreased expression of ZNF287 mRNA | CTD | PMID:22714537 | titanium dioxide | decreases expression | EXP | | 6480464 | titanium dioxide results in decreased expression of ZFP287 mRNA | CTD | PMID:27760801 | titanium dioxide | increases expression | EXP | | 6480464 | titanium dioxide results in increased expression of ZFP287 mRNA | CTD | PMID:29264374 | trichostatin A | decreases expression | ISO | ZNF287 (Homo sapiens) | 6480464 | trichostatin A results in decreased expression of ZNF287 mRNA | CTD | PMID:24935251 and PMID:26272509 | trichostatin A | multiple interactions | ISO | ZNF287 (Homo sapiens) | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF287 mRNA | CTD | PMID:27188386 | valproic acid | multiple interactions | ISO | ZNF287 (Homo sapiens) | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF287 mRNA | CTD | PMID:27188386 | valproic acid | decreases expression | ISO | ZNF287 (Homo sapiens) | 6480464 | Valproic Acid results in decreased expression of ZNF287 mRNA | CTD | PMID:23179753 more ... | |